tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Spectral Medical Files Base Shelf Prospectus to Raise $100 Million

Story Highlights
  • Spectral Medical filed a base shelf prospectus to distribute up to $100 million in securities.
  • The company revised its Annual Information Form to update clinical trial details and enhance transparency.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Spectral Medical Files Base Shelf Prospectus to Raise $100 Million

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Spectral Medical ( (TSE:EDT) ) has issued an announcement.

Spectral Medical Inc. has filed a final short form base shelf prospectus with Canadian securities regulators, allowing it to qualify the distribution of up to $100 million in securities over a 25-month period. This move is part of the company’s strategy to expand its financial capabilities and support its ongoing clinical trials and operations. Additionally, Spectral revised its Annual Information Form to include updates on the Tigris clinical trial and disclose a director’s past involvement with a bankrupt corporation. These actions are expected to enhance transparency and potentially strengthen investor confidence.

The most recent analyst rating on (TSE:EDT) stock is a Hold with a C$1.00 price target. To see the full list of analyst forecasts on Spectral Medical stock, see the TSE:EDT Stock Forecast page.

Spark’s Take on TSE:EDT Stock

According to Spark, TipRanks’ AI Analyst, TSE:EDT is a Neutral.

Spectral Medical’s overall stock score is primarily influenced by its challenging financial performance, which poses significant risks. However, recent positive corporate events, including promising trial results and progress towards FDA approval, provide potential upside. Technical analysis and valuation factors offer a neutral to slightly negative outlook.

To see Spark’s full report on TSE:EDT stock, click here.

More about Spectral Medical

Spectral Medical Inc. is a late-stage theranostic company focused on advancing therapeutic options for sepsis and septic shock. The company is seeking U.S. FDA approval for its product Toraymyxin™ (PMX), a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. PMX is already approved for use in Japan, Europe, and Canada, and has been used in over 360,000 cases worldwide. Spectral is listed on the Toronto Stock Exchange under the symbol EDT.

YTD Price Performance: 172.22%

Average Trading Volume: 176,406

Technical Sentiment Signal: Buy

Current Market Cap: C$423.3M

For detailed information about EDT stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1